Cost-effectiveness of Genetic Testing of Endocrine Tumor Patients Using a Comprehensive Hereditary Cancer Gene Panel
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae300 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Attila Patócs und 7 weiteren Autor:innen. Beteiligte Einrichtung: HUN-REN Hereditary Tumors Research Group, Hungarian Research Network, H-1089 Budapest, Hungary. Hauptthemen laut MEDLINE: Genetic Testing, Cost-Benefit Analysis, Endocrine Gland Neoplasms, Genetic Predisposition to Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hungarian Scientific Research Grant of the National Research, Development and Innovation, Office Fund of the Ministry of Culture and Innovation under the National Laboratories Program, National Tumor Biology Laboratory.
Abstract (Originalsprache)
Introduction
Heterogenous clinical manifestations, overlapping phenotypes, and complex genetic backgrounds are common in patients with endocrine tumors. There are no comprehensive recommendations for genetic testing and counseling of these patients compared to other hereditary cancer syndromes. The application of multigene panel testing is common in clinical genetic laboratories, but their performance for patients with endocrine tumors has not been assessed.
Methods
As a national reference center, we prospectively tested the diagnostic utility and cost-efficiency of a multigene panel covering 113 genes representing genetic susceptibility for solid tumors; 1279 patients (including 96 cases with endocrine tumors) were evaluated between October 2021 and December 2022 who were suspected to have hereditary tumor syndromes.
Results
The analytical performance of the hereditary cancer panel was suitable for diagnostic testing. Clinical diagnosis was confirmed in 24% (23/96); incidental findings in genes not associated with the patient's phenotype were identified in 5% (5/96). A further 7% of pathogenic/likely pathogenic variants were detected in genes with potential genetic susceptibility roles but currently no clear clinical consequence. Cost-benefit analysis showed that the application of a more comprehensive gene panel in a diagnostic laboratory yielded a shorter turnaround time and provided additional genetic results with the same cost and workload.
Discussion
Using comprehensive multigene panel results in faster turnaround time and cost-efficiently identifies genetic alterations in hereditary endocrine tumor syndromes. Incidentally identified variants in patients with poor prognoses may serve as a potential therapeutic target in tumors where therapeutic possibilities are limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HUN-REN Hereditary Tumors Research Group, Hungarian Research Network, H-1089 Budapest, Hungary.
- Department of Laboratory Medicine, Semmelweis University, H-1089 Budapest, Hungary.
- Department of Molecular Genetics and the National Tumor Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Center, H-1122 Budapest, Hungary.
- Semmelweis University, National Academy of Scientist Education, H-1085 Budapest, Hungary.
- Department of Oncology Biobank, National Institute of Oncology, Comprehensive Cancer Center, H-1122 Budapest, Hungary.
ORCID-Profile: Attila Patócs, Henriett Butz
Förderung
- Hungarian Scientific Research Grant of the National Research, Development and Innovation
- Office Fund of the Ministry of Culture and Innovation under the National Laboratories Program
- National Tumor Biology Laboratory
- Hungarian Thematic Excellence Program
- NRDI
- New National Excellence Program of the Ministry of Human Capacities
- Bolyai Research Fellowship of the Hungarian Academy of Sciences
Zitieren
APA
Patócs, A., Nagy, P., Papp, J., Bozsik, A., Antal, B., Grolmusz, V. K., Pócza, T., & Butz, H. (2024). Cost-effectiveness of Genetic Testing of Endocrine Tumor Patients Using a Comprehensive Hereditary Cancer Gene Panel. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae300
Vancouver
Patócs A, Nagy P, Papp J, Bozsik A, Antal B, Grolmusz VK, et al. Cost-effectiveness of Genetic Testing of Endocrine Tumor Patients Using a Comprehensive Hereditary Cancer Gene Panel. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae300
BibTeX
@article{Patcs2024,
author = {Patócs, Attila and Nagy, Petra and Papp, János and Bozsik, Anikó and Antal, Bálint and Grolmusz, Vince Kornél and Pócza, Tímea and Butz, Henriett},
title = {Cost-effectiveness of Genetic Testing of Endocrine Tumor Patients Using a Comprehensive Hereditary Cancer Gene Panel},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae300}
}
EUVIMED